Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

418 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: morishita a. Aliment Pharmacol Ther. 2024 Jul;60(2):233-245. doi: 10.1111/apt.18037. Epub 2024 May 8. Aliment Pharmacol Ther. 2024. PMID: 38716823 Clinical Trial.
MicroRNA profiles in various hepatocellular carcinoma cell lines.
Morishita A, Iwama H, Fujihara S, Sakamoto T, Fujita K, Tani J, Miyoshi H, Yoneyama H, Himoto T, Masaki T. Morishita A, et al. Oncol Lett. 2016 Sep;12(3):1687-1692. doi: 10.3892/ol.2016.4853. Epub 2016 Jul 13. Oncol Lett. 2016. PMID: 27588118 Free PMC article.
Correlation between serum galectin-9 levels and liver fibrosis.
Fujita K, Niki T, Nomura T, Oura K, Tadokoro T, Sakamoto T, Tani J, Yoneyama H, Morishita A, Kuroda N, Arai T, Nishimoto N, Himoto T, Hirashima M, Masaki T. Fujita K, et al. Among authors: morishita a. J Gastroenterol Hepatol. 2018 Feb;33(2):492-499. doi: 10.1111/jgh.13851. J Gastroenterol Hepatol. 2018. PMID: 28618039
Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease.
Himoto T, Fujita K, Nomura T, Tani J, Morishita A, Yoneyama H, Haba R, Masaki T. Himoto T, et al. Among authors: morishita a. Diabetol Metab Syndr. 2017 Jun 13;9:45. doi: 10.1186/s13098-017-0243-z. eCollection 2017. Diabetol Metab Syndr. 2017. PMID: 28630652 Free PMC article.
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M. Ogawa C, et al. Among authors: morishita a. Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20. Oncology. 2017. PMID: 29258090 Free article. Clinical Trial.
418 results